GR3007158T3 - - Google Patents

Info

Publication number
GR3007158T3
GR3007158T3 GR930400394T GR930400394T GR3007158T3 GR 3007158 T3 GR3007158 T3 GR 3007158T3 GR 930400394 T GR930400394 T GR 930400394T GR 930400394 T GR930400394 T GR 930400394T GR 3007158 T3 GR3007158 T3 GR 3007158T3
Authority
GR
Greece
Prior art keywords
hav
amendable
virus
manufacture
attenuated
Prior art date
Application number
GR930400394T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3007158T3 publication Critical patent/GR3007158T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Physical Water Treatments (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Non-Flushing Toilets (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
GR930400394T 1987-08-06 1993-02-25 GR3007158T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8272087A 1987-08-06 1987-08-06

Publications (1)

Publication Number Publication Date
GR3007158T3 true GR3007158T3 (enExample) 1993-07-30

Family

ID=22173006

Family Applications (1)

Application Number Title Priority Date Filing Date
GR930400394T GR3007158T3 (enExample) 1987-08-06 1993-02-25

Country Status (16)

Country Link
US (1) US5521082A (enExample)
EP (1) EP0302692B1 (enExample)
JP (1) JPH0648980B2 (enExample)
KR (1) KR970001711B1 (enExample)
AT (1) ATE84067T1 (enExample)
AU (1) AU612168B2 (enExample)
CY (1) CY1773A (enExample)
DE (1) DE3877082T2 (enExample)
DK (1) DK173215B1 (enExample)
ES (1) ES2042751T3 (enExample)
GR (1) GR3007158T3 (enExample)
IE (1) IE61294B1 (enExample)
IL (1) IL87257A0 (enExample)
NZ (1) NZ225583A (enExample)
PT (1) PT88178B (enExample)
ZA (1) ZA885726B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913665D0 (en) * 1989-06-14 1989-08-02 Univ Birmingham Method of preparing vaccines against rna viruses
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
JPH0834362B2 (ja) * 1991-03-08 1996-03-29 ローム株式会社 電気部品取り外し機
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
GB9111230D0 (en) * 1991-05-24 1991-07-17 Wellcome Found Virus production
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
KR100762477B1 (ko) * 2001-05-31 2007-10-02 주식회사 포스코 고로의 출선구 개공장치
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2004016222A2 (en) * 2002-08-16 2004-02-26 Ohio University Hepatitis c viral-like particle purification
AU2003297039B2 (en) * 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
AU2016337598B2 (en) * 2015-10-15 2022-10-13 Biocon Limited Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
JP7874457B2 (ja) * 2022-06-28 2026-06-16 Ｋｍバイオロジクス株式会社 Ａ型肝炎ウイルスのクロマトグラフィー精製方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7216091A (enExample) * 1971-12-03 1973-06-05
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Also Published As

Publication number Publication date
EP0302692A2 (en) 1989-02-08
JPH0648980B2 (ja) 1994-06-29
PT88178B (pt) 1995-03-01
IE882407L (en) 1989-02-06
US5521082A (en) 1996-05-28
JPS6451080A (en) 1989-02-27
NZ225583A (en) 1991-07-26
DE3877082D1 (de) 1993-02-11
KR970001711B1 (ko) 1997-02-14
CY1773A (en) 1995-10-20
DE3877082T2 (de) 1993-06-03
KR890003407A (ko) 1989-04-14
AU2051888A (en) 1989-03-23
DK437988D0 (da) 1988-08-05
EP0302692B1 (en) 1992-12-30
DK173215B1 (da) 2000-04-03
EP0302692A3 (en) 1990-02-14
PT88178A (pt) 1989-06-30
ZA885726B (en) 1989-04-26
ATE84067T1 (de) 1993-01-15
IL87257A0 (en) 1988-12-30
ES2042751T3 (es) 1993-12-16
DK437988A (da) 1989-04-04
AU612168B2 (en) 1991-07-04
IE61294B1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
IE882407L (en) Purifying hepatitis a virus
HUT53148A (en) Process for producing vaccines against contamination by non-a, non-b hepatitis virus and diagnostics suitable for detecting contamination
DE3268361D1 (en) New vaccine and therapy against non-a non-b viral hepatitis, and their preparation process
FR2344629A1 (fr) Procede pour la purification et l'isolement de virus de l'hepatite utilisable pour la preparation d'un vaccin
DE3174765D1 (en) High titer production of hepatitis a virus
IL86635A0 (en) Canine coronavirus vaccine
DE3071225D1 (en) Influenza virus vaccines, process for preparing them and process for propagating influenza viruses
ES2165884T3 (es) Preparacion farmaceutica estable que no contiene actividad viral consistente en al menos un 70%, preferiblemente un 90% de inmunoglobulina a humana monomera, y procedimiento de preparacion.
ATE179428T1 (de) Verfahren zur herstellung von hepatitis antigenen und impfstoffen
IL76417A (en) Vaccine for hepatitis a virus based on strain hm-175
HUT47867A (en) Process for producing vaccine against infective peritonitis of cat
FI903143A0 (fi) Menetelmä ihmisen nuhaviruksen serotyypittämiseksi
JPS51118825A (en) A process for preparing heat stable iga and igm
NZ192271A (en) Inactivated feline infectious peritonitis (fip) vaccine
EP0179075A4 (en) HEMOGLOBIN WITH REDUCED VIRUS RISK AND THEIR PRODUCTION.
AU1668788A (en) Method of vaccination for hepatitis b virus
DE3279264D1 (en) Method of immunizing pigs against aujeszky's disease
EP0321020A3 (en) Process for preparing n-acyl-anilines
ATE209505T1 (de) Ein intranasaler trivalenter rinderimpfstoff der modifiziertes lebendes ibrv, pi3v und brsv enhält
JPS5747487A (en) Production of interferon
SG24594G (en) Novel process for purification of hepatitis A virions.
AU8277582A (en) Method for the preparation of a dna-hybride, containing the complementary genome of the hepatitis a virus, the dna- hybride itself, the plasmic vector contain it, the specific proteins of the virus coded by the dna-hybride and vaccines containing them
AU2713488A (en) Process for manufacturing antigens, vaccines and sera to combat bacterial or viral diseases and composition for implementing said process